AZD-2858 is a potent and selective inhibitor of glycogen synthase kinase-3 (GSK-3), an enzyme involved in multiple signaling pathways related to cell survival, inflammation, and metabolism. Its primary application lies in research settings for studying diseases where GSK-3 overactivity is implicated, such as neurodegenerative disorders including Alzheimer's disease. By inhibiting GSK-3, AZD-2858 helps reduce the hyperphosphorylation of tau protein, a key pathological feature in Alzheimer's, making it a valuable tool in preclinical models for evaluating potential neuroprotective strategies.

It has also been explored in studies related to mood disorders and bipolar disease due to GSK-3's role in regulating neuronal plasticity and behavior. Additionally, AZD-2858 shows potential in research on inflammatory conditions and diabetes, where modulation of GSK-3 can influence insulin signaling and inflammatory cytokine production. Due to its research-focused use, AZD-2858 is primarily applied in cellular and animal models to assess therapeutic pathways rather than in clinical treatment.